Abstract
AIM: We assessed the association between the presence and absence of androgen on the normal biodistribution of the positron emission tomography (PET) cellular proliferation imaging biomarker, [(18)F]-2'-Fluoro-5-methyl-1-beta-D-arabinofuranosyluracil ((18)F-FMAU), in mice. MATERIALS AND METHODS: Non-castrated (n=4) and castrated (n=4) athymic non-tumor-bearing male mice served as models for presence and absence, respectively, of androgen. MicroPET-CT scans were performed 1 h following tail vein administration of 200 uCi of (18)F-FMAU. Imaging was performed at baseline and then at 7-day intervals longitudinally for 35 days only in castrated mice following subcutaneous introduction of a 12.5 mg, 21-day release, dihydrotestosterone pellet. Mean standardized uptake values (SUV(mean)) were obtained for liver, heart, and muscle. Several two-group comparisons of average of SUV(mean) were performed. RESULTS: Pre-pellet baseline average SUV(mean) (±s.d.) values in castrated mice were significantly lower than baseline non-castrated values, increased on day 15 and reached peak values on day 28, at which time they were significantly higher than corresponding baseline levels in both non-castrated and pre-pellet castrated mice. The peak values decreased significantly following dihydrotestosterone withdrawal. CONCLUSION: There is a significant modulatory effect of androgen on normal (18)F-FMAU uptake levels in mice liver, heart and muscle tissues.